Probable linezolid-induced pancytopenia

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 16, Issue 5, 2005, Pages 286-288

  Lakhani, Nita ^a   Thompson, William ^a   Bombassaro, Anne Marie ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Adverse reaction; Linezolid; Pancytopenia

Indexed keywords

HEMOGLOBIN; LINEZOLID; VANCOMYCIN;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; BLOOD TRANSFUSION; CASE REPORT; CHRONIC KIDNEY DISEASE; DEHYDRATION; DIABETES MELLITUS; DIABETIC FOOT; DRUG WITHDRAWAL; ERYTHROCYTE; HEART DISEASE; HIGH RISK PATIENT; HUMAN; IRON DEFICIENCY ANEMIA; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OSTEOMYELITIS; OUTPATIENT; PANCYTOPENIA; RISK FACTOR;

EID: 28344452801     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2005/961613     Document Type: Article

References (15)

1. Zyvoxam product monograph. Compendium of Pharmaceutical Specialties. Ottawa: Canadian Pharmacists Association, 2004:2341-4.
2. Kuter DJ, Tillotson GS. Hematologic effects of antimicrobials: Focus on the oxazolidinone linezolid. Pharmacotherapy 2001;21:1010-3.
3. Moellering RC. Linezolid: The first oxazolidinone antimicrobial. Ann Intern Med 2003;138:135-42.
4. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother 2002;46:2723-6.
5. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: Experience from a compassionate-use program. Clin Infect Dis 2003;36:159-68.
6. Nimeiri HS, Nemiary DS. Challenges with linezolid therapy and reversible pancytopenia. Ann Hematol 2003;82:533.
7. Halpern M. Linezolid-induced pancytopenia. Clin Infect Dis 2002;35:347-8.
8. Tahir N. Serotonin syndrome as a consequence of drug-resistant infections: An interaction between linezolid and citalopram. J Am Med Dir Assoc 2004;5:111-3.
9. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
10. Sisson TL, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol 2002;57:793-7.
11. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003;47:2775-80.
12. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003;42:1129-40.
13. Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA 2001;285:1291.
14. Bernstein WB, Trotta RF, Rector JT, Tjaden JA, Barile AJ. Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother 2003;37:517-20.
15. Yunis AA. Chloramphenicol toxicity: 25 years of research. Am J Med 1989;87:44N-48N.